Microbiotica has raised $67 million in a series B funding round, the largest microbiome-related financing in Europe to date.
The round was co-led by Flerie Invest, a Swedish life science investor, and Tencent, a Chinese tech giant.
Microbiotica is focused on discovering and developing microbiome-based therapeutics and biomarkers, and will use the money to progress two oral live bacterial therapies, MB097 and MB310 into the clinic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze